{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:30:00Z","timestamp":1785216600397,"version":"3.55.0"},"reference-count":103,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Introduction: The introduction of the transdiagnostic approach in psychiatry shifts the focus from discrete diagnoses to shared symptoms across various disorders. The Transdiagnostic Global Impression\u2014Psychopathology (TGI-P) scale is a newly developed tool designed to assess psychiatric symptoms across diagnostic boundaries. It evaluates ten core symptom domains\u2014positive, negative, cognitive, manic, depressive, addiction, anxiety, sleep, hostility, and self-harm\u2014regardless of specific diagnoses. Objective: This study aims to evaluate the efficacy of cariprazine across these ten transdiagnostic symptom domains. Methods: A systematic literature review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches were performed on EMBASE and clinicaltrials.gov. Efficacy measures such as the Positive and Negative Syndrome Scale (PANSS), Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Hamilton Anxiety Rating Scale (HAM-A), and Columbia-Suicide Severity Rating Scale (C-SSRS) were used to assess cariprazine\u2019s effect on the ten transdiagnostic symptoms. Multilevel random-effects meta-analyses were conducted to evaluate the efficacy of cariprazine versus placebo in alleviating depressive and anxiety symptoms across clinical trials. Results: A total of 30 studies were included in the review. Cariprazine showed therapeutic benefits on positive, negative, manic, and depressive symptoms in specifically designed trials. Preliminary positive effects were seen on anxiety, hostility, and cognitive symptoms across disorders. However, specific trials have not been conducted for anxiety disorders or cognitive impairment. Meta-analyses demonstrated that cariprazine significantly reduces both depressive and anxiety symptoms compared to placebo. Cariprazine significantly improved sleep-related symptoms in both mania and depression trials. Suicidality was evaluated in non-suicidal populations, and no increase was observed. Addiction symptoms were part of the exclusion criteria in the RCTs, so they could not be assessed. Previous reports of cariprazine\u2019s anti-craving and anti-abuse effects come from real-world evidence rather than RCT data. Conclusions: Cariprazine appears to be promising in addressing a broad range of symptom domains across psychiatric conditions.<\/jats:p>","DOI":"10.3390\/ph18070995","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:08:44Z","timestamp":1751447324000},"page":"995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains"],"prefix":"10.3390","volume":"18","author":[{"given":"Agota","family":"Barabassy","sequence":"first","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-363X","authenticated-orcid":false,"given":"R\u00e9ka","family":"Csehi","sequence":"additional","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Borb\u00e1la","family":"Dombi","sequence":"additional","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szatm\u00e1ri","sequence":"additional","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Global Medical Division, Gedeon Richter Plc, 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_2","unstructured":"The World Health Organisation (2025, April 09). International Classification of Diseases, 11th Revision (ICD-11) 11th Edition. Available online: https:\/\/icd.who.int\/en\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1037\/ccp0000482","article-title":"Transdiagnostic approaches to mental health problems: Current status and future directions","volume":"88","author":"Dalgleish","year":"2020","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/wps.20631","article-title":"Transdiagnostic psychiatry: A systematic review","volume":"18","author":"Solmi","year":"2019","journal-title":"World Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/wps.20680","article-title":"Transdiagnostic psychiatry goes above and beyond classification","volume":"18","author":"Mansell","year":"2019","journal-title":"World Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lee, E., Lee, D., Baek, J.H., Kim, S.Y., and Park, W.Y. (2024). Transdiagnostic clustering and network analysis for questionnaire-based symptom profiling and drug recommendation in the UK Biobank and a Korean cohort. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-49490-7"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jpsychires.2023.03.003","article-title":"Transdiagnostic psychiatry: Symptom profiles and their direct and indirect relationship with well-being","volume":"161","author":"Kist","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamapsychiatry.2024.2652","article-title":"Prioritization of psychopathological symptoms and clinical characterization in psychiatric diagnoses: A narrative review","volume":"81","author":"Leucht","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euroneuro.2024.07.012","article-title":"The Transdiagnostic Global Impression\u2014Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice","volume":"88","author":"Correll","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_10","unstructured":"EMA 2017 (2025, February 01). Reagila smpc. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/reagila-epar-product-information_en.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Barab\u00e1ssy, \u00c1., Dombi, Z.B., and N\u00e9meth, G. (2024). D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115682"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kiss, B., Horti, F., and Bobok, A. (2012). Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr. Res., 136.","DOI":"10.1016\/S0920-9964(12)70588-1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_15","unstructured":"Goodwin, F.K., and Redfield Jamison, K. (2007). Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Oxford University Press. [2nd ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nn.4173","article-title":"Mesolimbic dopamine signals the value of work","volume":"19","author":"Hamid","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_17","first-page":"1","article-title":"Role for the mesocortical dopamine system in the motivating effects of cocaine","volume":"145","author":"Koob","year":"1994","journal-title":"NIDA Res. Monogr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nlm.2015.06.002","article-title":"Dopamine in the nucleus accumbens core, but not shell, increases during signaled food reward and decreases during delayed extinction","volume":"123","author":"Biesdorf","year":"2015","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","article-title":"The Neurobiology of Anhedonia and Other Reward-Related Deficits","volume":"35","author":"Markou","year":"2012","journal-title":"Trends Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D3 receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"Leggio","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"ref_22","first-page":"9","article-title":"Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology","volume":"5","author":"Stahl","year":"2003","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_23","first-page":"497","article-title":"Effects of 5-HT1A receptor agonists and antagonists in rat models of anxiety","volume":"190","author":"Bardin","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yohn, C.N., Gergues, M.M., and Samuels, B.A. (2017). The role of 5-HT receptors in depression. Mol. Brain, 10.","DOI":"10.1186\/s13041-017-0306-y"},{"key":"ref_25","first-page":"93","article-title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies","volume":"1","author":"Millan","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Altman, D., Antes, G., Atkins, D., Barbour, V., Barrowman, N., and Berlin, J.A. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: Reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three Multisite Studies with Adolescents and Adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rosa, A.R., S\u00e1nchez-Moreno, J., Mart\u00ednez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Riel, W.V., and Ayuso-Mateos, J.L. (2007). Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin. Pract. Epidemol. Ment. Health, 3.","DOI":"10.1037\/t69921-000"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gps.930060208","article-title":"The cognitive drug research computerized assessment system for demented patients: A validation study","volume":"6","author":"Simpson","year":"1991","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: A proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results from an International, Phase III Clinical Trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: A randomised, double-blind, controlled trial","volume":"389","author":"Laszlovszky","year":"2017","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J. Affect. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","author":"Yatham","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley","year":"2020","journal-title":"Bipolar Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bdi.13421","article-title":"Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder","volume":"26","author":"McIntyre","year":"2024","journal-title":"Bipolar Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_50","first-page":"62","article-title":"Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacol. Bull."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1176\/appi.ajp.20220504","article-title":"Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study","volume":"180","author":"Sachs","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Riesenberg, R., Yeung, P.P., Rekeda, L., Sachs, G.S., Kerolous, M., and Fava, M. (2023). Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J. Clin. Psychiatry, 84.","DOI":"10.4088\/JCP.22m14643"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.15m10192","article-title":"The effect of Cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials","volume":"77","author":"Citrome","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jad.2024.04.084","article-title":"Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder","volume":"358","author":"Citrome","year":"2024","journal-title":"J. Affect. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","article-title":"Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II\/III trials","volume":"25","author":"Vieta","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Yatham, L.N., Vieta, E., McIntyre, R.S., Jain, R., Patel, M., and Earley, W. (2020). Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim. Care Companion CNS Disord., 22.","DOI":"10.4088\/PCC.20m02611"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/YIC.0000000000000500","article-title":"Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: A pooled post hoc analysis","volume":"39","author":"Jain","year":"2024","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2024.08.119","article-title":"Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data","volume":"366","author":"Vieta","year":"2024","journal-title":"J. Affect. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jad.2024.10.040","article-title":"Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"369","author":"Citrome","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1017\/S109285292200013X","article-title":"The efficacy of cariprazine on cognition: A post hoc analysis from phase II\/III clinical trials in bipolar mania, bipolar depression, and schizophrenia","volume":"28","author":"McIntyre","year":"2023","journal-title":"CNS Spectr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.03.032","article-title":"Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II\/III studies","volume":"215","author":"Earley","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_66","unstructured":"Boland, R., and Verduin, M. (2024). Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry, Wolters Kluwer. [11th ed.]."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists\u2014Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"ref_68","first-page":"934","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"349","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Carmassi, C., Dell\u2019Oste, V., Fantasia, S., Bordacchini, A., Bertelloni, C.A., Scarpellini, P., and Pedrinelli, V. (2024). A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1382013"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pappa, S., Kalniunas, A., Sharma, H., Raza-Syed, A., Kamal, M., and Larkin, F. (2022). Efficacy and safety of cariprazine augmentation in patients treated with clozapine: A pilot study. Ther. Adv. Psychopharmacol., 12.","DOI":"10.1177\/20451253221132087"},{"key":"ref_71","unstructured":"Fatemi, S.H., and Clayton, P.J. (2006). The Medical Basis of Psychiatry, Humana Press."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for psychosis and mood: Unique actions at D3, D2, and D1 dopamine receptor subtypes","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: A systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/YIC.0000000000000351","article-title":"The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: An observational study","volume":"36","author":"Rancans","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Dragasek, J., Dombi, Z.B., Acsai, K., Dzurilla, V., and Barab\u00e1ssy, \u00c1. (2024). The management of patients with predominant negative symptoms in Slovakia: A 1-year longitudinal, prospective, multicentric cohort study. Eur. Psychiatry, 67.","DOI":"10.1192\/j.eurpsy.2024.1757"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Pappa, S., Kalniunas, A., and Maret, J. (2023). Cariprazine for negative symptoms in early psychosis: A pilot study with a 6-month follow-up. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1183912"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0000000000000568","article-title":"Cariprazine as a maintenance treatment in dual schizophrenia: A 6-month observational study in patients with schizophrenia and cannabis use","volume":"40","author":"Szerman","year":"2024","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Rodriguez Cruz, J., Sahlsten Sch\u00f6lin, J., and Hjorth, S. (2021). Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.727666"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/NDT.S298005","article-title":"Cariprazine in three acute patients with schizophrenia: A real-world experience","volume":"17","author":"Montes","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Gentile, A., Marini, S., Matarazzo, I., De Berardis, D., and Ventriglio, A. (2022). Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report. Psychiatry Res. Commun., 2.","DOI":"10.1016\/j.psycom.2022.100048"},{"key":"ref_81","first-page":"11","article-title":"Clinical Experiences with Cariprazine in Schizophrenic Patients with Comorbid Substance Abuse","volume":"5","author":"Carmassi","year":"2019","journal-title":"Evid.-Based Psychiatr. Care"},{"key":"ref_82","first-page":"8","article-title":"Experiences of Switching to Cariprazine","volume":"5","author":"Palumbo","year":"2019","journal-title":"Evid.-Based Psychiatr. Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/JCP.0000000000001074","article-title":"Metabolic syndrome reversal with cariprazine","volume":"39","author":"Halaris","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajad.13241","article-title":"Case Series: Cariprazine for treatment of methamphetamine use disorder","volume":"31","author":"Truong","year":"2022","journal-title":"Am. J. Addict."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: Presentation of a case report","volume":"40","author":"Ricci","year":"2021","journal-title":"J. Addict. Dis."},{"key":"ref_86","first-page":"3","article-title":"A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine","volume":"15","author":"Moran","year":"2023","journal-title":"Cureus"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Vannucchi, T., Taddeucci, C., and Tatini, L. (2022). Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.878889"},{"key":"ref_88","unstructured":"Sanders, L.O., and Miller, J.J. (2025, June 03). Cariprazine May Decrease Substance Abuse in Patients with Bipolar I Disorder. Psychiatric Times 2019, 36. Available online: https:\/\/www.psychiatrictimes.com\/view\/cariprazine-may-decrease-substance-abuse-patients-bipolar-i-disorder."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","article-title":"Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice","volume":"28","author":"Martinotti","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhao, F., Cheng, Z., Piao, J., Cui, R., and Li, B. (2022). Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.947785"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Furczyk, K., Schutov\u00e1, B., Michel, T.M., Thome, J., and B\u00fcttner, A. (2013). The neurobiology of suicide\u2014A Review of post-mortem studies. J. Mol. Psychiatry, 1.","DOI":"10.1186\/2049-9256-1-2"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kiss, B., Laszlovszky, I., Kr\u00e1mos, B., Visegr\u00e1dy, A., Bobok, A., L\u00e9vay, G., Lendvai, B., and Rom\u00e1n, V. (2021). Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders. Biomolecules, 11.","DOI":"10.3390\/biom11010104"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Fava, M., Masand, P.S., Maletic, V., Chen, C., Adams, J.L., and Kerolous, M. (2025). Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. J. Clin. Psychiatry, 86.","DOI":"10.4088\/JCP.24m15506"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/13696998.2025.2513766","article-title":"Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States","volume":"28","author":"McIntyre","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Del Sol Calderon, P., Izquierdo de la Puente, A., Fern\u00e1ndez Fern\u00e1ndez, R., and Garc\u00eda Moreno, M. (2023). Use of cariprazine as an impulsivity regulator in an adolescent with non suicidal self-injury and suicidal attempts. Case report. Eur. Psychiatry, 66.","DOI":"10.1192\/j.eurpsy.2023.1553"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.smrv.2006.08.003","article-title":"The involvement of dopamine in the modulation of sleep and waking","volume":"11","author":"Monti","year":"2007","journal-title":"Sleep Med. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40263-012-0036-8","article-title":"Orexin (Hypocretin) Receptor Agonists and Antagonists for Treatment of Sleep Disorders","volume":"27","author":"Mieda","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_98","first-page":"1265","article-title":"Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness Tarja","volume":"23","author":"Strecker","year":"1997","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Huedo-Medina, T.B., Kirsch, I., Middlemass, J., Klonizakis, M., and Siriwardena, A.N. (2012). Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: Meta-analysis of data submitted to the Food and Drug Administration. BMJ, 345.","DOI":"10.1136\/bmj.e8343"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: A pooled analysis of eight phase II\/III studies","volume":"17","author":"Sebe","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Valencia Carlo, Y.E., Saracco-Alvarez, R.A., Valencia Carlo, V.A., V\u00e1zquez Vega, D., Natera Rey, G., and Escamilla Orozco, R.I. (2023). Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1189768"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jad.2017.08.040","article-title":"The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study","volume":"225","author":"Ketter","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.2147\/NDT.S337785","article-title":"The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review","volume":"17","author":"Kalniunas","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:04Z","timestamp":1760032984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":103,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18070995"],"URL":"https:\/\/doi.org\/10.3390\/ph18070995","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}